IP Library Granted Patent US 9,808,469
Granted Patent B2
US 9,808,469 · App. 15/314,342 · Granted Nov 7, 2017

Antitumor activity of multi-kinase inhibitors in triple negative breast cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,808,469
App. No.
15/314,342
Granted
Nov 7, 2017
Kind
B2
Abstract

A composition comprising a) a compound of Formula (I), where R 1 , R 2 , and R 3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof, R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are, each one and independently, hydrogen, hydroxyl or an —OR 4 group, where R 4 is a protector group according to the previous definition; and b) at least one chemotherapeutic agent, suitable for use in the treatment of Breast Cancer.

Claims (13)

1. A composition comprising

a) a compound of Formula (III)

and

b) at least one chemotherapeutic agent selected from carboplatin, docetaxel and olaparib.

2. The composition according to claim 1 , wherein the at least one chemotherapeutic agent is carboplatin.

3. The composition according to claim 1 , wherein the at least one chemotherapeutic agent is docetaxel.

4. The composition according to claim 1 , wherein the at least one chemotherapeutic agent is olaparib.

5. The composition according to claim 1 , wherein said composition is a pharmaceutical composition.

6. A method of treating breast cancer in a patient, said method comprising administering to a patient in need thereof of an effective dose of the composition of claim 1 .

7. A method for producing a pharmaceutical composition, which comprises mixing:

a) a compound of Formula (III)

and

b) at least one chemotherapeutic agent selected from carboplatin, docetaxel and olaparib.

Assignments (3)
SECURITY INTEREST Recorded Feb 18, 2026
From: ORPHAI THERAPEUTICS INC.
To: ACADIA WOODS PARTNERS, LLC, AS AGENT
Reel/Frame 074910/0274 →
SECURITY INTEREST Recorded Jun 23, 2025
From: ORPHAI THERAPEUTICS INC.
To: ACADIA WOODS PARTNERS, LLC
Reel/Frame 071697/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2016
From: OCANA FERNANDEZ, ALBERTO; PANDIELLA ALONSO, ATANASIO; MORIS VARAS, FRANCISCO
To: ENTRECHEM, S.L.
Reel/Frame 040725/0445 →